Apple (NASDAQ:AAPL) suppliers largely recover from yesterday’s plunge after Lumentum cut its guidance on weaker orders from a large customer. The recovery comes even...
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals Inc., to manufacture finished pharmaceutical...
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. AmerisourceBergen (NYSE:ABC) is a stock that can certainly grab...
For Immediate ReleaseChicago, IL – March 25, 2020 – Stocks in this week’s article are Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) , ConforMIS Inc....
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. Its segments include Finished pharmaceutical products and API products. The Finished pharmaceutical products segment manufactures, markets and distributes Primatene Mist, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs, as well as certain contract manufacturing. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Glucagon for injection emergency kit is indicated for the treatment of severe hypoglycemia.